CALM-1 (Bellus/GSK) – closed for inclusion
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm
Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)
Main inclusion criteria
- Refractory Chronic Cough
- Persistent cough for ≥ 1year
- No other significant or progressive respiratory disorder
- No uncontrolled asthma
Contact
anja.delporte@uzgent.be, tel. 09 332 02 28